Abstract
Background:
Prostate cancer (PCa) is a common malignancy and a leading cause of cancer death among men in the United States with African-American (AA) men having the highest incidence and mortality rates. Given recent results from admixture mapping and genome-wide association studies for PCa in AA men, it is clear that many risk alleles are enriched in men with West African genetic ancestry.
Methods:
A total of 77 ancestry informative markers (AIMs) within surrounding candidate gene regions were genotyped and haplotyped using Pyrosequencing in 358 unrelated men enrolled in a PCa genetic association study at the Howard University Hospital between 2000 and 2004. Sequence analysis of promoter region single-nucleotide polymorphisms (SNPs) to evaluate disruption of transcription factor-binding sites was conducted using in silico methods.
Results:
Eight AIMs were significantly associated with PCa risk after adjusting for age and West African ancestry. SNP rs1993973 (intervening sequences) had the strongest association with PCa using the log-additive genetic model (P=0.002). SNPs rs1561131 (genotypic, P=0.007), rs1963562 (dominant, P=0.01) and rs615382 (recessive, P=0.009) remained highly significant after adjusting for both age and ancestry. We also tested the independent effect of each significantly associated SNP and rs1561131 (P=0.04) and rs1963562 (P=0.04) remained significantly associated with PCa development. After multiple comparisons testing using the false discovery rate, rs1993973 remained significant. Analysis of the rs156113–, rs1963562–rs615382l and rs1993973–rs585224 haplotypes revealed that the least frequently found haplotypes in this population were significantly associated with a decreased risk of PCa (P=0.032 and 0.0017, respectively).
Conclusions:
The approach for SNP selection utilized herein showed that AIMs may not only leverage increased linkage disequilibrium in populations to identify risk and protective alleles, but may also be informative in dissecting the biology of PCa and other health disparities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun MJ et al. Family history and risk of fatal prostate cancer. Epidemiology 1997; 8: 653–657.
Berndt SI, Dodson JL, Huang WY, Nicodemus KK . A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 2006; 175: 1613–1623.
Ntais C, Polycarpou A, Ioannidis JP . Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 1395–1402.
Kostner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J . The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009; 29: 3511–3536.
Raimondi S, Johansson H, Maisonneuve P, Gandini S . Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009; 30: 1170–1180.
McCullough ML, Bostick RM, Mayo TL . Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 2009; 29: 111–132.
Rebbeck TR, Rennert H, Walker AH, Panossian S, Tran T, Walker K et al. Joint effects of inflammation and androgen metabolism on prostate cancer severity. Int J Cancer 2008; 123: 1385–1389.
Sun J, Turner A, Xu J, Grönberg H, Isaacs W . Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 2007; 25: 250–259.
Li H, Tai BC . RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res 2006; 12: 5713–5719.
Vaarala MH, Mattila H, Ohtonen P, Tammela TL, Paavonen TK, Schleutker J . The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer 2008; 122: 2511–2516.
Zhenhua L, Tsuchiya N, Narita S, Inoue T, Horikawa Y, Kakinuma H et al. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Lett 2005; 225: 237–243.
Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 2004; 64: 8461–8467.
Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS . CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 928–932.
Risio M, Venesio T, Kolomoets E, Armaroli P, Gallo F, Balsamo A, et al., BECaP Working Group. Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiol 2011; 35: e18–e24.
Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M et al. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 2010; 31: 1597–1603.
Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, Johnson-Pais T, Beuten J et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 2010; 10: 326.
Beuten J, Gelfond JA, Franke JL, Shook S, Johnson-Pais TL, Thompson IM et al. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev 2010; 19: 588–599.
Shea PR, Ishwad CS, Bunker CH, Patrick AL, Kuller LH, Ferrell RE . RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans. Prostate 2008; 68: 354–359.
Chen L, Davey Smith G, Evans DM, Cox A, Lawlor DA, Donovan J et al. Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev 2009; 18: 2874–2881.
Bonilla C, Hooker S, Mason T, Bock CH, Kittles RA . Prostate cancer susceptibility loci identified on chromosome 12 in African Americans. PLoS One 2011; 6: e16044.
Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T et al. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate 2008; 68: 1790–1797.
Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P et al. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 2006; 43: 507–511.
Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 2002; 110: 553–560.
Falush D, Stephens M, Pritchard JK . Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 2003; 164: 1567–1587.
Sole X, Guinó E, Valls J, Iniesta R, Moreno V . SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928–1929.
Schaid DJ, Sinnwell JP, Thibodeau SN . Robust multipoint identical-by-descent mapping for affected relative pairs. Am J Hum Genet 2005; 76: 128–138.
Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI . Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002; 277: 44462–44474.
Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10: 3291–3300.
Stone II R, Sabichi AL, Gill J, Lee IL, Adegboyega P, Dai MS et al. Identification of genes correlated with early-stage bladder cancer progression. Cancer Prev Res (Phila) 2010; 3: 776–786.
Wang SM, Ooi LL, Hui KM . Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 2011; 17: 6040–6051.
Surawska H, Ma PC, Salgia R . The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004; 15: 419–433.
Tang XX, Zhao H, Robinson ME, Cnaan A, London W, Cohn SL et al. Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. Med Pediatr Oncol 2000; 35: 656–658.
Tang XX, Zhao H, Robinson ME, Cohen B, Cnaan A, London W et al. Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci USA 2000; 97: 10936–10941.
Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M et al. Loss of EphB6 expression in metastatic melanoma. Int J Oncol 2003; 23: 1553–1559.
Raftopoulou M, Hall A . Cell migration: Rho GTPases lead the way. Dev Biol 2004; 265: 23–32.
Dema A, Raica M, Tudose N . Prognostic significance of neuroendocrine differentiation in carcinoma of the prostate. Rom J Morphol Embryol 1996; 42: 83–88.
Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW . Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304–310.
Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995; 274: 1277–1281.
D’Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH . Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003; 169: 1320–1324.
Acknowledgements
This project was supported in whole or in part with Federal funds from the National Center for Research Resources (NCRR) (UL1RR031975), National Institutes of health (NIH), through the Clinical and Translational Science Awards Program (CTSA), from the RCMI Program at Howard University (G12 RR003048), Division of Research Infrastructure, NCRR, NIH and the Howard University Cancer Center/Johns Hopkins Cancer Center Partnership (U54 CA091431), NCI, NIH.
Author contributions
LJR-S, VA, TM and GB participated in the design of the study, performed the statistical analysis and helped draft the manuscript. TM, BW, MA, WH, SH and MD carried out the molecular genetic studies, participated in SNP annotation, and helped draft the manuscript. CA, GD and RK conceived the study, participated in its design and coordination and helped to draft the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website
Supplementary information
Rights and permissions
About this article
Cite this article
Ricks-Santi, L., Apprey, V., Mason, T. et al. Identification of genetic risk associated with prostate cancer using ancestry informative markers. Prostate Cancer Prostatic Dis 15, 359–364 (2012). https://doi.org/10.1038/pcan.2012.19
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2012.19
Keywords
This article is cited by
-
Association of genetic ancestry with colorectal tumor location in Puerto Rican Latinos
Human Genomics (2019)
-
Relationship between West African ancestry with lung cancer risk and survival in African Americans
Cancer Causes & Control (2019)
-
Interest in genomic SNP testing for prostate cancer risk: a pilot survey
Hereditary Cancer in Clinical Practice (2015)